Abstract
Osteopontin (OPN) is a chemokine like phosphorylated glycoprotein that plays important role in cancer progression. Extensive research from various laboratories has demonstrated the likely role of OPN in regulating the cell signaling that ultimately controls tumor growth and metastasis. Several earlier reports indicated that OPN is associated with various cancers; but its functional role in carcinogenesis is still not well defined. Besides the role of OPN in tumor biology, several studies have demonstrated the pathophysiological role of OPN in diverse biological events. This review will focus on recent advances in understanding the molecular mechanism by which OPN regulates a series of signaling cascades through activation of various kinases and transcription factors that ultimately control the expression of downstream effector genes, which contribute to tumor progression and angiogenesis in vitro and animal models. We will also provide evidences that suggest the enhanced expression of OPN is not only associated with several tumor types, but its level of expression is directly correlated to various stages of the clinical specimens of breast and prostate cancers. These studies may be useful for identifying novel OPN-based therapeutic approach for the treatment of cancer.
Keywords: Osteopontin, cell signaling, tumor progression, metastasis, angiogenesis
Current Molecular Medicine
Title: The Multifaceted Roles of Osteopontin in Cell Signaling, Tumor Progression and Angiogenesis
Volume: 6 Issue: 8
Author(s): Goutam Chakraborty, Shalini Jain, Reeti Behera, Mansoor Ahmed, Priyanka Sharma, Vinit Kumar and Gopal C. Kundu
Affiliation:
Keywords: Osteopontin, cell signaling, tumor progression, metastasis, angiogenesis
Abstract: Osteopontin (OPN) is a chemokine like phosphorylated glycoprotein that plays important role in cancer progression. Extensive research from various laboratories has demonstrated the likely role of OPN in regulating the cell signaling that ultimately controls tumor growth and metastasis. Several earlier reports indicated that OPN is associated with various cancers; but its functional role in carcinogenesis is still not well defined. Besides the role of OPN in tumor biology, several studies have demonstrated the pathophysiological role of OPN in diverse biological events. This review will focus on recent advances in understanding the molecular mechanism by which OPN regulates a series of signaling cascades through activation of various kinases and transcription factors that ultimately control the expression of downstream effector genes, which contribute to tumor progression and angiogenesis in vitro and animal models. We will also provide evidences that suggest the enhanced expression of OPN is not only associated with several tumor types, but its level of expression is directly correlated to various stages of the clinical specimens of breast and prostate cancers. These studies may be useful for identifying novel OPN-based therapeutic approach for the treatment of cancer.
Export Options
About this article
Cite this article as:
Chakraborty Goutam, Jain Shalini, Behera Reeti, Ahmed Mansoor, Sharma Priyanka, Kumar Vinit and Kundu C. Gopal, The Multifaceted Roles of Osteopontin in Cell Signaling, Tumor Progression and Angiogenesis, Current Molecular Medicine 2006; 6 (8) . https://dx.doi.org/10.2174/156652406779010803
DOI https://dx.doi.org/10.2174/156652406779010803 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lung Cancer: Are we up to the Challenge?
Current Genomics Synthesis, Molecular Docking and Pharmacological Study of Pyrimidothiadiazinones and its bis-derivatives
Letters in Drug Design & Discovery Two Panels of Steroid Receptor Luciferase Reporter Cell Lines for Compound Profiling
Combinatorial Chemistry & High Throughput Screening Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Functional Interplay between RNA-Binding Protein HuR and microRNAs
Current Protein & Peptide Science Microbubbles as Drug Delivery Systems in Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Cisplatin Resistance and Transcription Factors
Current Medicinal Chemistry - Anti-Cancer Agents Synthesis of Bicyclic Aryl Thiazolines with Selective Anti-Proliferative Effects on Human Cancer Cell Lines
Letters in Organic Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Evaluation of <sup>177</sup>Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
Current Radiopharmaceuticals RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy
Current Pharmaceutical Design Some Developments Regarding Functional Food Products (Functional Foods)
Current Nutrition & Food Science Modulation of Photosensitization Processes for an Improved Targeted Photodynamic Therapy
Current Medicinal Chemistry A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer
Current Medical Imaging Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets MicroRNAs and Cancer Therapy – From Bystanders to Major Players
Current Medicinal Chemistry Polymers for Drug Eluting Stents
Current Pharmaceutical Design